Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 17 years ago
QualityStocks
Vyteris, Inc. (OTC BB: VYTR)
Tags Rodman & Renshaw
Related Post
-
Xeriant Inc. (XERI) Builds Innovation Ecosystem Focused on Advanced Technologies, Commercialization
Xeriant is focused on acquiring, developing and commercializing transformative technologies with applications across multiple industrial…
-
TechForce Robotics Inc. (NGTF): Proving Practical Solutions for the Industry’s Fatigued Areas
Hospitality operators are adopting robotics to target the most physically demanding jobs in hotels, venues,…
-
Drilling Assay Results Boost Deposit Potential, Demonstrates High-Grade Gold Intervals and Continuity for LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF), Setting Stage for Forthcoming PEA
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may…